<SEC-DOCUMENT>0000950170-24-139789.txt : 20241223
<SEC-HEADER>0000950170-24-139789.hdr.sgml : 20241223
<ACCEPTANCE-DATETIME>20241223183130
ACCESSION NUMBER:		0000950170-24-139789
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20241223
DATE AS OF CHANGE:		20241223

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pyxis Oncology, Inc.
		CENTRAL INDEX KEY:			0001782223
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				831160910
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-92951
		FILM NUMBER:		241575213

	BUSINESS ADDRESS:	
		STREET 1:		321 HARRISON AVENUE
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02118
		BUSINESS PHONE:		(617) 221-9059

	MAIL ADDRESS:	
		STREET 1:		321 HARRISON AVENUE
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02118

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sullivan Lara
		CENTRAL INDEX KEY:			0001769457
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	MAIL ADDRESS:	
		STREET 1:		C/O REXAHN PHARMACEUTICALS, INC.
		STREET 2:		15245 SHADY GROVE ROAD, SUITE 455
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<headerData>
<submissionType>SCHEDULE 13D/A</submissionType>
<previousAccessionNumber>0000905148-21-000683</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001769457</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>
</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>4</amendmentNo>
<securitiesClassTitle>Common Stock, par value $0.001 per share</securitiesClassTitle>
<dateOfEvent>12/23/2024</dateOfEvent>
<previouslyFiledFlag>false</previouslyFiledFlag>
<issuerInfo>
<issuerCIK>0001782223</issuerCIK>
<issuerCUSIP>747324101</issuerCUSIP>
<issuerName>Pyxis Oncology, Inc.</issuerName>
<address>
<street1 xmlns="http://www.sec.gov/edgar/common">321 Harrison Avenue</street1>
<city xmlns="http://www.sec.gov/edgar/common">Boston</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">MA</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">02118</zipCode>
</address>
</issuerInfo>
<authorizedPersons>
<notificationInfo>
<personName>Pamela Connealy</personName>
<personPhoneNum>(617) 351 2575</personPhoneNum>
<personAddress>
<street1 xmlns="http://www.sec.gov/edgar/common">321 Harrison Avenue</street1>
<city xmlns="http://www.sec.gov/edgar/common">Boston</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">MA</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">02118</zipCode>
</personAddress>
</notificationInfo>
</authorizedPersons>
</coverPageHeader>
<reportingPersons>
<reportingPersonInfo>
<reportingPersonCIK>0001769457</reportingPersonCIK>
<reportingPersonNoCIK>N</reportingPersonNoCIK>
<reportingPersonName>Lara Sullivan</reportingPersonName>
<fundType>PF</fundType>
<legalProceedings>N</legalProceedings>
<citizenshipOrOrganization>X1</citizenshipOrOrganization>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>6624699</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>6624699</sharedDispositivePower>
<aggregateAmountOwned>6624699</aggregateAmountOwned>
<isAggregateExcludeShares>N</isAggregateExcludeShares>
<percentOfClass>10.3</percentOfClass>
<typeOfReportingPerson>IN</typeOfReportingPerson>
</reportingPersonInfo>
</reportingPersons>
<items1To7>
<item1>
<securityTitle>Common Stock, par value $0.001 per share</securityTitle>
<issuerName>Pyxis Oncology, Inc.</issuerName>
<issuerPrincipalAddress>
<street1 xmlns="http://www.sec.gov/edgar/common">321 Harrison Avenue</street1>
<city xmlns="http://www.sec.gov/edgar/common">Boston</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">MA</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">02118</zipCode>
</issuerPrincipalAddress>
<commentText>This Amendment No. 4 to Schedule 13D ("Amendment No. 4") is being filed by the undersigned, pursuant to Rule 13d-2(a) under the Act, with respect to the Common Stock, $0.001 par value per share (the "Shares"), of Pyxis Oncology, Inc. (the "Issuer"), whose principal executive offices are located at 321 Harrison Avenue, Boston, Massachusetts 02118. This Amendment No. 4 amends and supplements the statement on Schedule 13D filed with the U.S. Securities and Exchange Commission (the "SEC") on October 22, 2021 (the "Original Schedule 13D"), as amended by Amendment No. 1 filed on May 23, 2022, Amendment No. 2 filed on April 4, 2023 and Amendment No. 3 filed on April 3, 2024 (together with this Amendment No. 4, the "Schedule 13D"). Capitalized terms used herein and not otherwise defined in this Amendment No. 4 have the meanings previously defined in the Schedule 13D. Except as specifically provided herein, this Amendment No. 4 does not modify any of the information previously reported in the Schedule 13D.</commentText>
</item1>
<item2>
<filingPersonName>Lara Sullivan</filingPersonName>
<principalBusinessAddress>321 Harrison Street, Boston, Massachusetts 02118</principalBusinessAddress>
<principalJob>President and Chief Executive Officer, Pyxis Oncology, Inc.</principalJob>
<hasBeenConvicted>No</hasBeenConvicted>
<convictionDescription>No</convictionDescription>
<citizenship>United States of America</citizenship>
</item2>
<item3>
<fundsSource>Item 3 of the Schedule 13D is hereby amended and supplemented as follows:
In connection with Lara Sullivan's role as Chief Executive Officer of the Issuer, on December 23, 2024, the Issuer granted the Reporting Person a stock option to purchase 1,135,000 Shares at an exercise price of $1.67 per share. Such stock options vest in full on December 23, 2025, subject to the Reporting Person's continued employment through the vesting date.</fundsSource>
</item3>
<item4>
<transactionPurpose>Item 4 of the Schedule 13D is hereby amended and supplemented as follows:
The response to Item 3 of this Amendment No. 4 is incorporated by reference herein.</transactionPurpose>
</item4>
<item5>
<percentageOfClassSecurities>Item 5 of the Schedule 13D is hereby amended and supplemented as follows:
As of the date hereof, the Reporting Person may be deemed to be the beneficial owner of 6,624,699 Shares, representing approximately 10.3% of the total number of shares outstanding. This amount includes: (i) an aggregate 4,220,817 Shares obtainable upon exercise of options, certain of which are subject to vesting upon the Reporting Person's continued employment through the applicable vesting date; and (ii) 537,335 Shares obtainable upon vesting of RSUs, all of which are subject to vesting upon the Reporting Person's continued employment through the applicable vesting date.
The foregoing beneficial ownership percentage is based on the sum of (i) 59,465,729 Shares outstanding as of November 11, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 12, 2024, plus (ii) the 4,220,817 Shares issuable upon exercise of options granted to the Reporting Person, and (iii) the 537,335 Shares issuable upon vesting of RSUs granted to the Reporting Person, each of (ii) and (iii) which have been added to the total Shares outstanding in accordance with Rule 13d-(d)(1)(i) under the Act.</percentageOfClassSecurities>
<numberOfShares>The response to Item 5(a) of this Amendment No. 4 is incorporated by reference herein.</numberOfShares>
<transactionDesc>The response to Item 3 of this Amendment No. 4 is incorporated by reference herein. Other than as disclosed in this Amendment No. 4, there have been no transactions in the Shares by the Reporting Person effected during the past sixty days.</transactionDesc>
</item5>
</items1To7>
<signatureInfo>
<signaturePerson>
<signatureReportingPerson>Lara Sullivan</signatureReportingPerson>
<signatureDetails>
<signature>/s/ Lara Sullivan</signature>
<title>Lara Sullivan, President and Chief Executive Officer</title>
<date>12/23/2024</date>
</signatureDetails>
</signaturePerson>
</signatureInfo>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
